Drug interactions
Ibrutinib + Lorlatinib
Severity: Moderate
Ibrutinib and Lorlatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A and may reduce ibrutinib plasma concentrations. Lower ibrutinib exposure could reduce its anti-tumour effect.
What this interaction means in plain words
Ibrutinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ibrutinib belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Lorlatinib induces intestinal and hepatic CYP3A4, increasing the first-pass and systemic clearance of ibrutinib, a sensitive CYP3A substrate.
What to do
Consider an alternative to lorlatinib or monitor closely for loss of ibrutinib response. Avoid combining with strong CYP3A inducers, and use a moderate inducer only with clinical monitoring.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ibrutinib and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Ibrutinib
- Abciximab + Ibrutinib Major
- Acetylsalicylic acid + Ibrutinib Major
- Alteplase + Ibrutinib Major
- Amobarbital + Ibrutinib Major
- Apalutamide + Ibrutinib Major
- Apixaban + Ibrutinib Major
Frequently asked questions
Can I take Ibrutinib with Lorlatinib?
MediHelp rates the interaction as moderate. Ibrutinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A and may reduce ibrutinib plasma concentrations. Lower ibrutinib exposure could reduce its anti-tumour effect.
How serious is the interaction between Ibrutinib and Lorlatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Consider an alternative to lorlatinib or monitor closely for loss of ibrutinib response. Avoid combining with strong CYP3A inducers, and use a moderate inducer only with clinical monitoring.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
